AP02, an inhaled formulation of nintedanib being developed by Avalyn Pharma, was well tolerated by both healthy people…
Articles by Margarida Maia, PhD
AP01, Avalyn Pharma’s pirfenidone solution for inhalation, may have fewer side effects than the oral formulation now used to…
KIN001, an experimental oral treatment of idiopathic pulmonary fibrosis (IPF), was more effective than Esbriet (pirfenidone) at easing lung fibrosis…
Bellerophon Therapeutics has gotten the green light to cut by about half the number of patients who may enter REBUILD,…
Algernon Pharmaceuticals has filed for orphan drug status for NP-120 (ifenprodil), an experimental oral medicine for patients with…
A molecular test, called the Envisia Genomic Classifier, may predict which patients with idiopathic pulmonary fibrosis (IPF) will progress…
Less than 14 months after stopping its GALACTIC-1 study for certain patients due to safety concerns, Galecto has hit…
Coenzyme Q10 (CoQ10), an antioxidant found naturally in the body and some foods, may help airway basal stem cells survive…
Dosing has begun in healthy volunteers in a Phase 1 clinical trial of ISM001-055, a small molecule potential treatment of …
Pliant Therapeutics will start testing, in trial, a higher dose of its investigational oral small molecule PLN-74809, an anti-fibrotic…